Valeant Pharmaceuticals CEO Joe Papa likes to refer to his company as a start-up, even though Valeant has been around for years and has plenty of products on the market. I understand where Papa is coming from, though, since he’s trying to rebuild the embattled drugmaker.
His reference got me to thinking: What if investors thought of Gilead Sciences (NASDAQ: GILD) as a start-up? I suspect this different perspective would make the big biotech appear much more attractive to investors than it seems to have been lately. Here’s why.